» Articles » PMID: 2551444

Inhibition of Platelet-activating Factor- and Zymosan-activated Serum-induced Chemotaxis of Human Neutrophils by Nedocromil Sodium, BN 52021 and Sodium Cromoglycate

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 1989 Aug 1
PMID 2551444
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

1. Inflammatory cells such as eosinophils and neutrophils are thought to contribute actively to the pathogenesis of asthma since they infiltrate into the lung tissue. These cells are mobilized by lipid-like and protein-like chemotactic factors. As illustrative examples of both groups, platelet-activating-factor (Paf) and zymosan-activated-serum (ZAS) were used in this study. The inhibitory effects of nedocromil sodium, the Paf antagonist BN 52021 and sodium cromoglycate on Paf- and ZAS-induced neutrophil chemotaxis were evaluated. 2. All tested drugs inhibited Paf-induced neutrophil chemotaxis with approximately the same potency (IC50 approximately 1 nM). 3. Nedocromil sodium and sodium cromoglycate were equally potent in inhibiting ZAS-induced neutrophil chemotaxis (IC50 = 0.1-1 microM), whereas BN 52021 was considerably less potent (IC30 = 10 microM). 4. To find out whether the drugs tested could inhibit early events in cell activation, their capacity to inhibit Paf- and ZAS-induced cytosolic free Ca2+-mobilization was investigated. BN 52021, at a concentration of 100 microM, completely inhibited Paf-induced Ca2+-mobilization and inhibited ZAS-induced Ca2+-mobilization by about 50%. Nedocromil sodium and sodium cromoglycate were ineffective.

Citing Articles

Cromolyn sodium for the prevention of chronic lung disease in preterm infants.

Ng G, Ohlsson A Cochrane Database Syst Rev. 2017; 1:CD003059.

PMID: 28114736 PMC: 6464952. DOI: 10.1002/14651858.CD003059.pub3.


Nedocromil sodium. An updated review of its pharmacological properties and therapeutic efficacy in asthma.

Brogden R, Sorkin E Drugs. 1993; 45(5):693-715.

PMID: 7686465 DOI: 10.2165/00003495-199345050-00007.


Inhibition of neutrophil and eosinophil induced chemotaxis by nedocromil sodium and sodium cromoglycate.

Bruijnzeel P, Warringa R, Kok P, KREUKNIET J Br J Pharmacol. 1990; 99(4):798-802.

PMID: 2163279 PMC: 1917545. DOI: 10.1111/j.1476-5381.1990.tb13009.x.


PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Koltai M, Hosford D, Guinot P, Esanu A, Braquet P Drugs. 1991; 42(2):174-204.

PMID: 1717219 DOI: 10.2165/00003495-199142020-00002.


Mechanistic aspects of cromolyn sodium action on the alveolar macrophage: inhibition of stimulation by soluble agonists.

Holian A, Hamilton R, Scheule R Agents Actions. 1991; 33(3-4):318-25.

PMID: 1659157 DOI: 10.1007/BF01986580.


References
1.
Kay A . The mode of action of anti-allergic drugs. Clin Allergy. 1987; 17(2):153-64. View

2.
Lucas A, Shuster S . Cromolyn inhibition of protein kinase C activity. Biochem Pharmacol. 1987; 36(4):562-5. DOI: 10.1016/0006-2952(87)90368-6. View

3.
Kok P, Hamelink M, Kijne A, Verhagen J, Koenderman L, Bruynzeel P . Arachidonic acid can induce leukotriene C4 formation by purified human eosinophils in the absence of other stimuli. Biochem Biophys Res Commun. 1988; 153(2):676-82. DOI: 10.1016/s0006-291x(88)81148-3. View

4.
Hutson P, Holgate S, Church M . Inhibition by nedocromil sodium of early and late phase bronchoconstriction and airway cellular infiltration provoked by ovalbumin inhalation in conscious sensitized guinea-pigs. Br J Pharmacol. 1988; 94(1):6-8. PMC: 1853941. DOI: 10.1111/j.1476-5381.1988.tb11493.x. View

5.
Koenderman L, Kok P, Hamelink M, Verhoeven A, Bruijnzeel P . An improved method for the isolation of eosinophilic granulocytes from peripheral blood of normal individuals. J Leukoc Biol. 1988; 44(2):79-86. DOI: 10.1002/jlb.44.2.79. View